Beijing CoSci Med Tech

Beijing CoSci Med-Tech is a clinical-stage biopharmaceutical company focused on developing innovative antibody therapies for metabolic diseases, particularly diabetes. The company's lead candidate, volagidemab, is a fully human monoclonal antibody that acts as a glucagon receptor antagonist. By blocking glucagon signaling, the therapy aims to reduce excessive glucose production by the liver, offering a potential new treatment paradigm for both Type 1 and Type 2 diabetes. CoSci Med-Tech operates in close collaboration with REMD Biotherapeutics to advance its pipeline through clinical trials in China and globally. The company is headquartered in Beijing and has received significant backing from prominent venture capital firms to support its research and development efforts.